Search Results for :


Castle Biosciences Announces Data Presentation at the Society for Melanoma Research 2016 Congress Demonstrating Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management

Friendswood, TX – November 10, 2016 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the clinical impact of its gene expression profile (GEP) test DecisionDx®-Melanoma on patient management decisions. The test uses tumor biology to provide an individual risk of recurrence in … Read More


In the Lab: A Conversation with Federico Monzon, M.D., President-elect, AMP

Federico Monzon, M.D., chief medical officer of Castle Biosciences, entered the pathology field in the early 2000s and was among the first professionals to enjoy formal accredited recognition as a molecular pathologist. In that time his work has taken him from University of Pittsburgh Medical Center, Houston Methodist Hospital, and Baylor College of Medicine to … Read More


Castle Biosciences Announces Launch of New Eye Cancer Test to Measure Expression of PRAME Gene

Friendswood, TX – October 10, 2016 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the launch of DecisionDx®-PRAME, a gene expression profile (GEP) test designed to measure gene expression levels of PRAME (Preferentially Expressed Antigen in Melanoma). PRAME expression has been associated with an increased risk of … Read More


Study Results with Castle Biosciences’ Uveal Melanoma Gene Expression Test Published in Journal of Oncology

Friendswood, TX—August 10, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of clinical data on DecisionDx®-UM, its gene expression profile (GEP) test to predict metastasis in patients diagnosed with uveal melanoma (UM). The paper, “Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test … Read More


Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in Stage I and II Cohort Study at 2016 AAD Summer Meeting

Boston, MA—July 28, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the results from a study evaluating the performance of its gene expression profile (GEP) test DecisionDx®-Melanoma in a cohort of 356 Stage I and II melanoma patients. The data confirm findings from two previously published multicenter clinical … Read More


Results of New Study with Castle Biosciences’ Skin Melanoma Gene Expression Test Published in Current Medical Research and Opinion

Friendswood, TX—July 11, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of a prospectively designed, multicenter, decision impact study of its gene expression profile (GEP) test for cutaneous melanoma. The DecisionDx®-Melanoma GEP test accurately predicts metastatic risk independent of current diagnostic modalities including AJCC staging. … Read More


Castle Biosciences Selected to Showcase Thriving Texas Biotechnology and Life Sciences Industries at BIO International Convention

Castle Biosciences was recently selected by the Texas Governor’s office to help showcase the state’s growing biotechnology and life sciences industries at a state-sponsored exhibit at the 2016 BIO International Convention, the largest global biotechnology event. The Company was featured among industry leaders in Texas such as the Cancer Prevention Research Institute of Texas (CPRIT), … Read More


Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in 334-Patient Performance Cohort Study at ASCO 2016

Results confirm accuracy of DecisionDx-Melanoma to identify recurrence risk
A second independent, prospective study confirms test accuracy
Chicago, IL—June 6, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the results from a study evaluating the performance of its gene expression profile (GEP) test, DecisionDx®-Melanoma, in 334 new melanoma … Read More


Castle Biosciences Announces New Clinical Data Presentations at ASCO 2016 Underscoring the Accuracy and Clinical Utility of Gene Expression Profile Test for Cutaneous Melanoma

Three data presentations focused on studies of DecisionDx-Melanoma test
Company will also present data on test in development for predicting cancer
recurrence in soft tissue sarcoma
Friendswood, TX—May 19, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that several abstracts on the Company’s gene expression profile (GEP) tests … Read More